Bristol-myers Squibb Compnay

Astrazeneca Ab

Astra Zeneca U.k. Limited

Pfizer Corporation

Bristol-myers Squibb Holdings Ireland

Bristol-myers Squibb Holdings Ireland Unlimited Company

Jatin M Patel

Prakash V Parab

Mandar V Dali

Ravindra W Tejwani

Dilbir S Bindra

Yongmei Wu

Nipa Vatsaraj

Li Tao

Divyakant S Desai

Peter Timmins

Kyle Martin

Admassu Abebe

Divyakant Desai

Charles C Frost

Chandra Vemavarapu

Jingpin Jia

Terry D Wilson

Hemant N Joshi

Chandra Vema-Varapu

Yongemei Wu

The present invention relates to bilayer tablet formulations comprising metformin extended release (XR) or reduced mass metformin XR formulation as the first layer, an SGLT2 inhibitor formulation as the second layer, and optionally a film coating. The present invention provides methods of preparing the bilayer tablet formulations and methods of treating diseases or disorders associated with SGLT2 activity employing the bilayer tablet formulations.

Bilayer tablet formulations

Compositions comprising crystalline apixaban particles having a Dequal to or less than 89 &#x3bc;m, and a pharmaceutically acceptable carrier, are substantially bioequivalent and can be used to for the treatment and/or prophylaxis of thromboembolic disorders.

Apixaban formulations

Pharmaceutical formulations are provided which are in the form of capsules or tablets for oral use and which include a medicament dapagliflozin or its propylene glycol hydrate and a pharmaceutical acceptable carrier therefor, which formulation is designed for immediate release.

Pharmaceutical formulations containing an SGLT2 inhibitor

The crystalline, stable methanesulfonate salt of nefazodone showed significantly higher intrinsic dissolution in water and THAM buffer (pH 7.5) compared to other salts of nefazodone. The faster dissolution rate of this salt at neutral pH suggests better dissolution and absorption in the intestine, allowing controlled release of nefazodone for oral formulations.

Salt form of nefazodone for use in extended release formulations

Growing community of inventors

New Brunswick, NJ, United States of America

Jatin M Patel